| Methods |
RCT.
Double‐masked.
Active controlled. |
| Participants |
374 people with POAG (62%) or OHT (only 188 participants examined with perimetry twice).
Racial constitution is not reported.
Inclusion criteria: IOP between 23 and 35 mmHg (untreated).
Exclusion criteria: patients using more than 2 ocular hypotensive agents, visual acuity below 20/100, abnormally low heart rate or blood pressure, long‐term treatment with any other topical or systemic alpha‐adrenoceptor agonist or antagonist, treatment with adrenergic‐augmenting psychotropic drugs, dry eye, asymmetry of IOP of more than 5 mmHg, extensive visual field loss, ocular surgery or laser within 6 months, c/d‐ratio of 0.8 or more. |
| Interventions |
Brimonidine 0.2% twice daily.
Timolol 0.5% twice daily. |
| Outcomes |
IOP.
Incidence of visual field defect or defect progression. |
| Notes |
1 year follow up.
Drop‐outs due to adverse events: 35 brimonidine (25 ocular and 10 systemic adverse events), 4 timolol (2 ocular and 2 systemic adverse events).
Most patients have been treated with opical beta‐blocker before washout of the study.
Visual field analysis available for subgroup only, comprising 77 patients recieving brimonidine and 111 with timolol. The difference between groups in proportion of patients participating in visual field analysis subgroup poses questions about randomisation. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
